Typically, the starting dose in a Phase 1 trial is too low to show efficacy. For CDR Life, observing immunological activity and biomarker improvement in their very first patient was a rare and remarkable event that provided the first tangible sign their scientific platform could become a real therapeutic.

By treating patients before their tumors are surgically removed, Infinitopes can analyze the resected tissue. This provides direct evidence of CD8 T cell infiltration in response to the vaccine—a powerful, mechanistic proof-point that is impossible for competitors testing in later-stage patients.

The Rampart study's main contribution wasn't its specific drug data, but that it became the second positive trial in the adjuvant kidney cancer space. This balanced the 'scorecard' against multiple negative trials, reinforcing the general principle that early immune therapy is beneficial.

The most common investor misconception is that cancer vaccines have "never worked." The key rebuttal is that past failures targeted generic, shared antigens. The new generation of vaccines is fundamentally different, targeting specific mutations unique to each patient's tumor, which changes the entire paradigm.

An analysis of over 17,000 oncology drug development trajectories revealed that trials incorporating biomarkers had almost twice the overall success probability (10%) compared to those without (5%). This success boost is most significant in early-phase (Phase 1 and 2) trials.

Contrary to the belief that AI needs massive datasets, Dr. Joseph Juraji's approach with NetraAI focuses on finding small, specific patient subpopulations within small trials. This allows the identification of a drug's 'superpower' without the need for big data, transforming trial economics.

The Keynote 942 study didn't just show clinical improvement; it demonstrated that the neoantigen vaccine expanded specific T-cell clones associated with positive patient response. This confirms the therapy's intended biological mechanism of action, a critical step for validating this new class of cancer treatment.

Even though companies like Moderna (mRNA) and Transgene (viral vector) use different platforms, positive results from any of them help validate the entire individualized neoantigen approach for investors and clinicians. The massive unmet medical need ensures the market is large enough to support multiple successful players.

Unconventionally, Infinitopes' first-in-human trial targets neoadjuvant patients (newly diagnosed, pre-surgery). This provides cleaner efficacy signals compared to trials in heavily pre-treated patients and enables unique analysis of resected tumors to prove the vaccine's mechanism, a key differentiator from competitors.